Page 1670 - Clinical Small Animal Internal Medicine

1608 Index

globulins 649–650 glucose metabolism 1209–1210 hazard rates see incidence rates
VetBooks.ir diagnosis 1102–1103 glycated hemoglobin 96–97 HCC see hepatocellular carcinoma
see also hyperglycemia;
HBT see heart‐based tumors
glomerular disease 1101–1107
hypoglycemia
etiology/pathophysiology 1101,
HCM see hypertrophic
1102 glycogen storage disease cardiomyopathy
history and clinical signs 1102 (GSD) 105–106 HDDS see high‐dose dexamethasone
prognosis 1107 glycoprotein hormones 36–38 suppression
signalment 1101 glycosuria 66 HDO see high‐definition oscillometry
treatment 1103–1107, 1104, 1105 GMC see giant migrating contractions HE see hepatic encephalopathy
glomerular filtration rate (GFR) GME see granulomatous head trauma 748–758
acute kidney injury 1089–1091, meningoencephalitis clinical assessment 750–753,
1093, 1095 GN see glomerulonephropathy 751–752, 752
feline hyperthyroidism 79 gonadotropin‐releasing hormone confirmation of injury and
hypothermia 432 (GnRH) 37–38, 1160 diagnosis 753–755, 754
phosphorus homeostasis and GP see general proprioceptive injury‐related intracranial
disorders 1083–1084 G‐protein 31, 75–76 physiology 748
ureteral obstruction 1118 GR see glucocorticoid receptors monitoring parameters 751
urethral obstruction 1112 granularity 513, 513, 521–522, 526 pathophysiology of brain
urolithiasis 1149, 1151 granulomas 667 injury 748–750, 750
glomerulonephropathy granulomatous meningoencephalitis prognosis 758
(GN) 1169–1170 (GME) 780, 797, 799, 801 refractory head trauma 757–758
glucagonoma 1299–1300, 1492 gross deformities 449–450 treatment 755–757
glucocorticoid receptors (GR) 50 growth hormone (GH) 38, 44–47 hearing 739
glucocorticoids growth hormone‐releasing hormone heart‐based tumors
allergic skin diseases (GHRH) 38, 43 (HBT) 1271–1275
1414–1415, 1417 growth plates 1509–1511, 1510 heart failure (HF)
approach to the dermatologic GSA see general somatic afferent acute life‐threatening heart
patient 1395 GSD see glycogen storage disease failure 194–197, 195
atopic dermatitis 1409–1410 GSE see general somatic efferent additional therapies 197
canine chronic bronchitis 308 gut microbiota see dysbiosis antithrombotics 188, 191–192
canine hypothyroidism 72 GVE see general visceral efferent beta‐adrenergic blockers 187,
cirrhosis 709 gynecologic cancers 1317–1320 190–191
cutaneous adverse food diagnosis 1317–1320 calcium channel blockers 188, 191,
reactions 1422 epidemiology 1317–1319 193
diabetes mellitus 93 etiology/pathophysiology cardiogenic shock 415
feline bronchial asthma 1317–1319 chronic heart failure 185–192,
300–301, 303 history and clinical signs 187–188
hypoadrenocorticism 1317–1319 classification 177–178
81, 84–88 ovarian tumors 1319–1320 compensatory phase 179–181
hypoglycemia 107 prognosis 1318–1320 components of the circulatory
juvenile cellulitis 1446–1448 signalment 1317–1319 system 175
meningoencephalitis and treatment 1318–1320 cough suppression 194
meningomyelitis 800–801 uterine tumors 1317–1318 determinants of normal cardiac
metabolic bone diseases 1517 vaginal tumors 1318–1319 function 175–177
metabolic diseases 677–678 determinants of ventricular systolic
miscellaneous skin diseases h function 176–177
1499, 1504 H2RA see histamine‐2 receptor dietary modifications 188, 192
oral cavity and salivary glands antagonists diuretics 186, 187, 192–196, 195
537, 543 H3N2 virus 865–867, 1036 etiology 176
otitis externa/media 1475, H3N8 virus 865–867, 1036 failing heart 177–183
1477, 1479 HA see hydroxyapatite hemodynamics and development of
paraneoplastic syndromes 1218 HAC see hyperadrenocorticism pulmonary edema 183
pituitary‐dependent HAI see nocosomial and multidrug‐ initial insult 178–179
hyperadrenocorticism 51–52 resistant infections long‐term adaptive
urolithiasis 1126–1127 happiness 1560 responses 180–181